Supporting information

Ruthenium complexes bearing glucosyl ligands are able to inhibit the amyloid aggregation of short Histidine-peptides

Daniele Florio¹, Sara La Manna¹, Alfonso Annunziata^b, Ilaria Iacobucci^{3,4}, Vittoria Monaco^{3,4}, Concetta Di Natale⁵, Valentina Mollo⁶, Francesco Ruffo³, Maria Monti^{3,4}, and Daniela Marasco^{1,*}

¹Department of Pharmacy, University of Naples Federico II, 80131, Naples, Italy

³Department of Chemical Sciences, University of Naples Federico II, 80126, Naples, Italy

⁴CEINGE Biotecnologie Avanzate "Franco Salvatore" S.c.a r.l., 80131, Naples, Italy

⁵Interdisciplinary Research Centre on Biomaterials (CRIB), Department of Ingegneria Chimica del

Materiali e della Produzione Industriale (DICMAPI), University Federico II, 80125 Naples, Italy

⁶Center for Advanced Biomaterials for Healthcare, Istituto Italiano di Tecnologia (IIT), Largo Barsanti e Matteucci 53, Naples 80125, Italy.



Fig. S1 Overlay of ThT fluorescence emission intensity of Ru-MBAG (A), Ru-Oxa (B) and Ru-Cym (C) complexes at indicated time.



Fig. S2 Overlay of aromatic intrinsic fluorescence assay of Ru-MBAG (A), Ru-Oxa (B) and Ru-Cym complexes (C) at indicated time.



Figure S3. ESI-MS spectra of isolated BSP $_{27-32}$ (A0, A24 panels) and $\beta_2 m_{83-88}$ (B0, B24 panels) at 0 and 24h



Figure S4. Conformational analysis of BSP₂₇₋₃₇ at 1mM, phosphate buffer 10mM.



Figure S5. Histogram of CD absolute values of $\beta_2 m_{83-88}$ at indicated times.



Figure S7. TEM analysis at t=4 d of BSP₂₇₋₃₂ peptide (A) alone, and in presence of (B) Ru-Cym, (C) Ru-MBAG and (D) Ru-Oxa.



Fig. S8 TEM analysis of $\beta 2m_{83-88}$ peptide alone at t 0 and 4 d (A and E) and in presence of Ru-Cym, Ru-MBAG and Ru-Oxa (B-D, t=0), (F-H, t= 4 d).